Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1987 1
2007 1
2008 1
2009 1
2010 1
2011 4
2013 2
2014 1
2015 1
2016 2
2017 2
2018 8
2019 4
2020 7
2021 9
2022 5
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 May 16:S0140-6736(24)00548-8. doi: 10.1016/S0140-6736(24)00548-8. Online ahead of print. Lancet. 2024. PMID: 38763154 Free article.
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, Petersen PM, Persad RA, Pugh CA, Saad F, Logue J, Payne H, Bower LC, Brawley C, Rauchenberger M, Barkati M, Bottomley DM, Brasso K, Chung HT, Chung PWM, Conroy R, Falconer A, Ford V, Goh CL, Heath CM, James ND, Kim-Sing C, Kodavatiganti R, Malone SC, Morris SL, Nabid A, Ong AD, Raman R, Rodda S, Wells P, Worlding J, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 May 16:S0140-6736(24)00549-X. doi: 10.1016/S0140-6736(24)00549-X. Online ahead of print. Lancet. 2024. PMID: 38763153 Free article.
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
Guo C, Sharp A, Gurel B, Crespo M, Figueiredo I, Jain S, Vogl U, Rekowski J, Rouhifard M, Gallagher L, Yuan W, Carreira S, Chandran K, Paschalis A, Colombo I, Stathis A, Bertan C, Seed G, Goodall J, Raynaud F, Ruddle R, Swales KE, Malia J, Bogdan D, Tiu C, Caldwell R, Aversa C, Ferreira A, Neeb A, Tunariu N, Westaby D, Carmichael J, Fenor de la Maza MD, Yap C, Matthews R, Badham H, Prout T, Turner A, Parmar M, Tovey H, Riisnaes R, Flohr P, Gil J, Waugh D, Decordova S, Schlag A, Calì B, Alimonti A, de Bono JS. Guo C, et al. Among authors: paschalis a. Nature. 2023 Nov;623(7989):1053-1061. doi: 10.1038/s41586-023-06696-z. Epub 2023 Oct 16. Nature. 2023. PMID: 37844613 Free PMC article.
The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer.
Adamson B, Brittain N, Walker L, Duncan R, Luzzi S, Rescigno P, Smith G, McGill S, Burchmore RJ, Willmore E, Hickson I, Robson CN, Bogdan D, Jimenez-Vacas JM, Paschalis A, Welti J, Yuan W, McCracken SR, Heer R, Sharp A, de Bono JS, Gaughan L. Adamson B, et al. Among authors: paschalis a. J Clin Invest. 2023 Nov 15;133(22):e169200. doi: 10.1172/JCI169200. J Clin Invest. 2023. PMID: 37751307 Free PMC article.
Critical role of antioxidant programs in enzalutamide-resistant prostate cancer.
Blatt EB, Parra K, Neeb A, Buroni L, Bogdan D, Yuan W, Gao Y, Gilbreath C, Paschalis A, Carreira S, DeBerardinis RJ, Mani RS, de Bono JS, Raj GV. Blatt EB, et al. Among authors: paschalis a. Oncogene. 2023 Jul;42(30):2347-2359. doi: 10.1038/s41388-023-02756-w. Epub 2023 Jun 24. Oncogene. 2023. PMID: 37355762 Free PMC article.
A Transgender Patient with Prostate Cancer: Lessons Learnt.
Chandran K, Grochot R, de Los Dolores Fenor De La Maza M, Yuan W, Gurel B, Miranda S, Paschalis A, Riisnaes R, Figueiredo I, Bogdan D, Sharp A, Carreira S, de Bono JS. Chandran K, et al. Among authors: paschalis a. Eur Urol. 2023 Apr;83(4):379-380. doi: 10.1016/j.eururo.2022.12.027. Epub 2023 Jan 4. Eur Urol. 2023. PMID: 36609007 No abstract available.
Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker.
Birmpilis AI, Paschalis A, Mourkakis A, Christodoulou P, Kostopoulos IV, Antimissari E, Terzoudi G, Georgakilas AG, Armpilia C, Papageorgis P, Kastritis E, Terpos E, Dimopoulos MA, Kalbacher H, Livaniou E, Christodoulou MI, Tsitsilonis OE. Birmpilis AI, et al. Among authors: paschalis a. Cells. 2022 Apr 22;11(9):1415. doi: 10.3390/cells11091415. Cells. 2022. PMID: 35563721 Free PMC article. Review.
Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer.
Sheehan B, Neeb A, Buroni L, Paschalis A, Riisnaes R, Gurel B, Gil V, Miranda S, Crespo M, Guo C, Jiménez Vacas J, Figueiredo I, Ferreira A, Welti J, Yuan W, Carreira S, Sharp A, de Bono J. Sheehan B, et al. Among authors: paschalis a. Clin Cancer Res. 2022 Jul 15;28(14):3104-3115. doi: 10.1158/1078-0432.CCR-21-4531. Clin Cancer Res. 2022. PMID: 35552383 Free PMC article.
50 results